Seeking Alpha

AMLN
Amylin Pharmaceuticals, Inc.

5/23/2012, 8:52 PM ET
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
AMLN Market Currents more »
  • May 15 Amylin Pharmaceuticals' (AMLN +6%) annual shareholder meeting is over and CEO Dan Bradbury made no comment on speculation the drug maker is talking to potential suitors, as has been reported. Bradbury did talk up prospects for its new diabetes drug Bydureon and Metreleptin, a potential new drug for metabolic disorder in rare diseases. (presentation)
    Comment!
    [Healthcare, On the Move]
AMLN in Focus more »
AMLN Instablog posts more »
  • Aerocrine AB Treating Inflammatory Airway Diseases
    Thu, Apr 12 • V.I.P. • Comment!
  • Market Astrology – Strategy Going Forward
    Tue, Apr 3 • Jeff Pierce • Comment!
  • VE Medical Sector Pick Amylin Pharma (AMLN,$AMLN) is Up More than 13%
    Wed, Dec 28, 2011 • Steve Hach • Comment!
  • Carl Icahn’s Investment Portfolio As Of Q4/2010
    Tue, Mar 15, 2011 • Dividend Sheet • Comment!
  • Amylin Pharmaceuticals (AMLN) is Undervalued
    Fri, Mar 4, 2011 • Hedge Fund Live • Comment!
Write a post on AMLN
AMLN StockTalks
AMLN vs. ETF Alternatives
Company Description

We are a biopharmaceutical company committed to improving the lives of people with diabetes, obesity and other diseases through the discovery, development and commercialization of innovative medicines. We are marketing two first-in-class medicines to treat diabetes, BYETTA® (exenatide) injection... More

Sector: Healthcare
Industry: Biotechnology
Country: United States